CRP and melanoma: The development of immunotherapies for melanoma has achieved great success, however, there are still a variety of immune-related adverse events, such as low relative lymphocyte count, C-reactive protein elevation, diarrhea, and increased drug resistance (47, 48) The management of immune-related adverse events is still under investigation, but ncRNAs have the potential to serve as therapeutic targets for preventing melanoma recurrence or increasing the sensitivity of melanoma to current therapies.